Affordable Access

deepdyve-link
Publisher Website

Living with Advanced Hormone-Sensitive Prostate Cancer and Treatment with Abiraterone and Androgen Deprivation Therapy: The Patient, Nursing and Physician Perspective

Authors
  • Collier, Tony1
  • Smith, Shievon2
  • Greenwood, Michelle2
  • Ng, Kenrick2, 3
  • 1 Prostate Cancer UK,
  • 2 Barts Health NHS Trust,
  • 3 UCL Cancer Institute,
Type
Published Article
Journal
Oncology and Therapy
Publisher
Springer Healthcare
Publication Date
Oct 09, 2020
Pages
1–11
Identifiers
DOI: 10.1007/s40487-020-00132-2
PMID: 33037517
PMCID: PMC7546153
Source
PubMed Central
Keywords
License
Unknown

Abstract

This article is co-authored by a patient with metastatic hormone-sensitive prostate cancer who is receiving abiraterone and androgen deprivation therapy treatment in Manchester, UK. The patient relates his personal experiences struggling with the diagnosis, his experience with treatment and the physical, emotional and psychosexual impact on his life. After his diagnosis, the patient has become an outspoken advocate and fundraiser for prostate cancer awareness and wants to ensure that novel treatments with proven efficacy and tolerability, such as abiraterone, are available for all men in his condition. The specialist nursing and physician perspectives, provided by healthcare professionals based in London who are not directly involved in this patient’s care, were written in response to the challenges and concerns highlighted by this patient. The role of the specialist nurse as a key healthcare professional in the cancer patient journey, particularly in managing the complex physical and emotional side effects of treatment, is highlighted in this perspective piece. The physician reviews the current difficulties of establishing an effective screening programme in prostate cancer, the common side effects of hormone treatment and the significant progress and challenges in novel drug development and prescription in metastatic hormone-sensitive prostate cancer. While written primarily from the perspective of a patient and healthcare professionals in England, many messages in this commentary would resonate with patients and professionals involved in the care of prostate cancer worldwide.

Report this publication

Statistics

Seen <100 times